<DOC>
	<DOCNO>NCT00866073</DOCNO>
	<brief_summary>This study open-label phase II trial investigate efficacy toxicity low-dose decitabine ( 5-aza-2'-deoxycytidine ) elderly patient acute myeloid leukemia ( AML ) eligible aggressive induction chemotherapy . AML patient age 60 year ( upper age limit ) previously receive eligible , standard induction treatment disease eligible trial . Decitabine administer 3 hour infusion 15 mg/m2 three time daily three consecutive day ( total dose 135 mg/m2 ) . In patient &gt; 20000 WBC/µl , treatment repeat 1 week later . In patient white blood cell exceed 50 000/μl , decitabine treatment precede cytoreductive dos hydroxyurea .</brief_summary>
	<brief_title>Study Low-Dose Intravenous Decitabine Patients Aged &gt; 60 Years With Acute Myeloid Leukemia</brief_title>
	<detailed_description>Hypothesis : If 4 course Decitabine none 12 patient achieves response ( complete partial remission , antileukemic effect ) , protocol stop . If least one response see among first 12 patient , 17 additional patient treat open , uncontrolled manner . If 3 29 patient response achieve , treatment consider effective study , otherwise consider ineffective . At preliminary analysis recruitment 29 patient , encourage result ( response rate , tolerability ) prompt continuation recruitment , plan inclusion least 60 patient , initiation plan large , control phase II follow-up trial . Unexpected toxicity carefully evaluate . 29 patient need first two step phase II study , least 60 patient plan extension recruitment . Expected study duration first two step 15-20 month , 35-40 month total include third step .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients older 60 year acute myeloid leukemia ( &gt; 30 % bone marrow blast ) qualifying , consent , standard induction chemotherapy immediate allografting life expectancy &gt; 3 month successful treatment performance status ECOG 0 , 1 , 2 ageadjusted normal cardiac , kidney , liver function ( creatinine &lt; 1.5 mg/dl unless leukemiarelated , total bilirubin &lt; 2.0 upper normal limit ) patient &gt; 50 000 leukocytes/µl initial cytoreduction accord protocol effective write informed consent AML FAB subtype M3 previous inductiontype chemotherapy MDS AML previous treatment Decitabine , 5azacytidine ATRA `` lowdose '' chemotherapy ( e.g.hydroxyurea , cytosine arabinoside , melphalan ) within 8 week prior Decitabine treatment , except cytoreduction leukocytosis &gt; 50 000/µl accord protocol patient &gt; 50 000 leukocytes/µl initial cytoreduction accord protocol ineffective treatment cytokine within previous 4 week concomitant use investigational drug malignancy remission ( previous chemotherapy malignancy exclusion criterion ) cardiac insufficiency NYHA IV HIV infection uncontrolled active infection psychiatric disorder interferes treatment know hypersensitivity retinoids contact lens</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>AML</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>Decitabine</keyword>
</DOC>